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suggest that a tumor-derived gene signature could be
found to be predictive for HCC late-recurrence (Bud-
hu et al., unpublished data). This is analogous to the
recent ﬁndings that both tumor and non-tumor-de-
rived gene signatures can predict HCC early-recur-
rence in multiple cohorts [4–9]. Thus, the jury is still
out and further studies are needed.
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A new French paradox: HBV vaccination
To the Editor:
In his recent article, DS Chen indicated that the hep-
atitis B vaccine was an innovation from France [1].
When listing the challenges that need to be overcome
to extend hepatitis B mass vaccination he could have ci-
ted France again. The percentage of one-year-olds
immunized with three doses of Hepatitis B in France
was 29% in 2006 (vs. 86% in Germany, a comparable
country), lower than most of the very poor countries
in the world [2].
Recently, a paper by a French team published in a
major journal concluded that ‘‘Engerix B vaccine ap-
pears to increase the risk of CNS inﬂammatory demye-
lination in childhood” [3]. A pre-publication release
campaign worsened the message in the newspapers.
This research was conducted with public funding
from several major national bodies. Evaluation could
have helped avoiding: (a) subgroup analyses without
a priori deﬁnition on the basis of known mechanisms
or in response to previous ﬁndings; (b) absence of
declaration of the number of analyses performed;
(c) lack of adjustment for multiple testing with tests
for heterogeneity [4]. These pitfalls are easy to
remember: Sleight showed, in a subgroup analysis
of patients from the ISIS- 2 trial, that aspirin therapy
was signiﬁcantly beneﬁcial for all patients except
those born under the astrological signs of Gemini
or Libra [5]!
Guidelines were generated to improve quality of epi-
demiological studies (eg ‘STrengthening the Reporting
of OBservational studies in Epidemiology’ (STROBE)
[6]. Funding agencies, reviewers and journals editors
must have actively endorsed these guidelines.
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Hepatitis B vaccine and multiple sclerosis: A case of repeated de´ja` vu?
To the Editor:
I cannot agree more with Braillon [1] that in revealing
the results of any study concerning the adverse reactions
of treatment or prevention measures, everyone in the
chain of releasing the information should be very pru-
dent. This is especially true in relation to the hepatitis
B vaccine.
The unusually low coverage of hepatitis B vaccina-
tion in France can be traced to the alleged concerns
about the safety of the hepatitis B vaccine. The allega-
tion started right after the country implemented an
active hepatitis B vaccination program in 1994–1995 tar-
geting at pre-adolescents in the ﬁrst year of secondary
schools as well as all infants [2]. Initially, the program
was highly successful with a coverage rate of 76% in
adolescents. During implementation of the program,
reports of demyelinating disorders of the central nervous
system (CNS) suspected to be associated with hepatitis
B vaccination started to appear. Despite the lack of cau-
sal association, the issue caught the attention of mass
media and, naturally, the general public then. The pres-
sure cumulated became so great that it led the French
health authority to suspend hepatitis B vaccination in
a school-based program on October 1, 1998. The French
government’s decision was immediately condemned by
the World Health Organization (WHO) and the French
pediatricians [3], because it will very possibly result in a
loss of public conﬁdence in hepatitis B vaccination, and
thus lead other countries to discontinue its use or decide
not to introduce a hepatitis B vaccination program that
is critical in the control of hepatitis B worldwide [4].
Indeed, the negative impact could be tremendous, if
not handled appropriately. To avoid unnecessary
negative impacts to our very successful mass hepatitis
B vaccination program in Taiwan [5], right after the sus-
pension of hepatitis B vaccine in France, Taiwan’s
Department of Health immediately issued a press release
to assure the safety and necessity of hepatitis B vaccina-
tion in the country. Fortunately, the French issue did
not ferment, and did not aﬀect our program.
A premature or immature release of the results of any
study concerning adverse reactions of the hepatitis B vac-
cines may be exploited by anti-vaccination groups, liabil-
ity lawyers, and most importantly, the media. Even if the
results are disproved ﬁnally, the media usually does not
report them, because of the loss of news worthiness [6].
The public’s initial wrong image remains, and becomes
an obstacle in the implementation of the vaccination pro-
gram. Unfortunately, despite the rejection of a causal
relationship between hepatitis B vaccine and multiple
sclerosis [7], reports suggesting a risk of multiple sclerosis
associated with recombinant hepatitis B vaccine still ap-
peared [8]. WHO responded quickly by denying the inter-
pretation of the results of the study [WHO Global
Advisory Committee on Vaccine Safety, September
2004; http://www.who.int/vaccine_safety/topics/hepati-
tisb/multiple_sclerosis/sept_04/en/]. The issue recurred
again recently, initiated after an article published by a
French group in early October 2008 [9]. Based on sub-
group analysis of children having followed the French
vaccine recommendations, it was concluded that
althoughhepatitis B vaccination does not increase the risk
of CNS inﬂammatory demyelination in children, the
Engerix hepatitis B vaccine appears to increase the risk,
especially for the conﬁrmed cases of multiple sclerosis.
Although the authors conceded that their results require
conﬁrmation in future studies [9], the conclusions of the
article very likely have had exerted another negative im-
pact on hepatitis B vaccination, at least in France. The
Global Advisory Committee on Vaccine Safety of WHO
again responded immediately by concluding that the
study did not provide convincing evidence that hepatitis
B vaccine, or use of any brand of the vaccine, is associated
with an increased risk of acute CNS inﬂammatory demy-
elination or multiple sclerosis [WHO Global Advisory
Committee on Vaccine Safety, October 8, 2008; http://
www.who.int/vaccine_safety/topics/hepatitisb/multiple_
sclerosis/oct_2008/en]. In the meantime, the French
health products safety agency (Afssaps) also responded
promptly in refuting the association [http://www.
